By: Ted Sweetser, Vice President, Strategic Partnerships, PurpleLab
Each year, the Cannes Lions International Festival of Creativity offers a glimpse into where marketing is headed. In 2026, one message became increasingly clear: healthcare is no longer simply adopting marketing innovation – it is helping shape where it goes next.
The hype around AI hasn’t gone anywhere, but it has matured. The conversation has shifted from purely speculatively (“look what this can do”) to outcomes-based (“show me what it actually delivers”).
A reverse JFK if you will, “Ask not what your enterprise can be doing to embrace AI, but what AI is able to deliver for your enterprise!” From CMOs, I heard this expressed as needing metrics to show how it helps growth, not just the cost savings that have long been trumpeted.
Here’s what stood out to me, and where pharma marketers in particular should be paying attention.
Quality vs quantity is becoming a false choice
Amazon’s marketers put it quite pithily in the print magazine they handed out at their port. A section on the “myths of AI” pointed out that the dichotomy of quantity vs quality does not hold true with the latest AI. This was born out in one of their creative venues where you could use their AI to generate a full creative marketing campaign for an invented company, based on a single sentence prompt, with a credible looking set of ads optimized to run against most of Amazon’s inventory in a few short minutes.
It was impressive enough that I’ll admit I was tempted by my own invented company (a hat store for pet birds), though not quite tempted enough to leave PurpleLab and chase it. The implication though, that we are ever closer to micro segmented content creation, is highly compelling even if our business vertical’s MLR processes mean it may lag a bit.
The frontier labs are getting serious about revenue
Outcomes are coming for the frontier AI labs. OpenAI is beginning to show interest in making revenue, debuting more about their ad strategy at Cannes, though amusingly their initial offerings are focused on brand awareness plays. It’s an early sign of where these platforms intend to monetize, and worth watching closely as DTC and HCP media opportunities inside large language models start to take shape.
In TV, OpenAP debuted a conversion tool that allows pooled measurement across a wide range of platforms – again pulling vast sums of media up against conversion data. The headline for me was that we’re buying on outcomes in TV land now. This is an important evolution for a channel that has historically been measured on reach and frequency, and it tracks with everything else going on at Cannes this year.
Agentic frameworks are connecting the dots
If there was one thing pharma marketers should take home from Cannes 2026, it’s that the media buyers and agencies that support them are implementing agentic frameworks to tie data together far more easily than before. These frameworks connect media to conversions and let marketers use conversational interfaces to pull real outcomes statements from that combined data. Work that would have taken months (optimistically) not long ago is collapsing into something far faster.
As a data jockey, I’m excited to see so much more of my less technical counterparts able to get into the saddle and learn what’s really working!